Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 93
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Surg Res ; 293: 239-247, 2024 01.
Artigo em Inglês | MEDLINE | ID: mdl-37802018

RESUMO

INTRODUCTION: Small bowel obstruction (SBO) is one of the most common causes for hospital admission in Ethiopia. The use of water-soluble contrast agents (WSCAs) such as Gastrografin to manage adhesive SBO can predict nonoperative resolution of SBO and reduce decision time to surgery and length of hospital stay. However, nothing is known about practice patterns and Gastrografin use in low-income settings. We sought to characterize current management practices, including use of WSCAs, as well as outcomes for patients with SBO in Addis Ababa, Ethiopia. METHODS: We conducted a mixed-methods study consisting of a survey of surgeons throughout Ethiopia and a retrospective record review at five public, tertiary care-level teaching hospitals in Addis Ababa. RESULTS: Of the 76 surgeons who completed the survey, 63% had heard of the use of WSCAs for SBO and only 11% used oral agents for its management. Chart review of 149 patients admitted with SBO showed the most common etiology was adhesion (39.6% of admissions), followed by small bowel volvulus (20.8%). Most patients (83.2%) underwent surgery during their admission. The most common diagnosis in patients who did not require surgery was also adhesion (68.0%), as well as for those who had surgery (33.9%), followed by small bowel volvulus (24.2%). CONCLUSIONS: The etiology of SBO in Ethiopia may be changing, with postoperative adhesions becoming more common than other historically more prevalent causes. Although a Gastrografin protocol as a diagnostic and potentially therapeutic aid for SBO is feasible in this population and setting, challenges can be anticipated, and future studies of protocol implementation and effectiveness are needed to further inform its utility in Ethiopia and other low-income and middle-income countries.


Assuntos
Obstrução Intestinal , Volvo Intestinal , Humanos , Diatrizoato de Meglumina/uso terapêutico , Volvo Intestinal/complicações , Estudos Retrospectivos , Estudos de Viabilidade , Etiópia , Obstrução Intestinal/etiologia , Obstrução Intestinal/terapia , Meios de Contraste , Aderências Teciduais/complicações , Aderências Teciduais/diagnóstico
2.
Med Sci Monit ; 27: e930046, 2021 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-33771966

RESUMO

BACKGROUND This retrospective cohort study from a single center aimed to compare patient outcomes following the use of the water-soluble contrast medium Gastrografin in the treatment of adhesive small bowel obstruction (ASBO) in patients with and without a history of chronic radiation enteropathy (CRE). MATERIAL AND METHODS Fifty-nine patients with CRE-induced small bowel obstruction (SBO) and 53 patients with ASBO at Jinling Hospital between April 2014 and February 2018 were enrolled. The patients were given 100 ml Gastrografin through a naso-jejunal tube, and erect abdominal X-rays were taken. Risk factors were found to be correlated with successful non-operative management (SNM) through statistical analyses. RESULTS The success rate of conservative treatment was higher in the Gastrografin group than in the control group (P<0.05). The Gastrografin challenge test is predictive of need for surgery in CRE-induced SBO and ASBO (AUC=0.860 and 0.749, respectively). The predictors associated with SNM in the CRE-induced SBO group were the total dose of radiotherapy, the Gastrografin challenge test, and previous operations for SBO. In the ASBO group, the predictors were the Gastrografin challenge test and previous operations for SBO. The operation rate of SBO patients with Gastrografin treatment was significantly lower than that in the control group (P<0.05). CONCLUSIONS The findings from this study showed that the use of Gastrografin effectively resolved ASBO in patients with and without a history of CRE, but a long-term requirement for surgery could not be avoided. The Gastrografin challenge may be a useful test to predict surgical outcomes.


Assuntos
Meios de Contraste/uso terapêutico , Diatrizoato de Meglumina/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Intestino Delgado/patologia , Lesões por Radiação/tratamento farmacológico , Adulto , Idoso , Estudos de Coortes , Feminino , Humanos , Obstrução Intestinal/cirurgia , Intestino Delgado/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Solubilidade , Aderências Teciduais , Resultado do Tratamento , Água
3.
Palliat Med ; 32(1): 294-298, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28805119

RESUMO

BACKGROUND: Intestinal obstruction and constipation are common conditions in patients with advanced neoplasms. Diatrizoate Meglumine has been used in the management of both these conditions without good quality evidence of its effectiveness and safety. AIM: This audit aimed to assess the usage, effectiveness and adverse effects of Diatrizoate Meglumine for intestinal obstruction and constipation in patients with advanced neoplasms. DESIGN: A retrospective chart review was undertaken. Descriptive statistics were utilised. SETTING/PARTICIPANTS: All patients with known advanced neoplasms admitted to Mater Health Services and St Vincent's Private Hospital Brisbane between January 2013 and October 2015; who were administered Diatrizoate Meglumine were included. RESULTS: Seventy-one patients received Diatrizoate Meglumine. The most common diagnoses were ovarian or primary peritoneal neoplasms (33.8%). Diatrizoate Meglumine was most commonly used for intestinal obstruction (59.2%). The median dose used per patient episode was 50 mL (range: 15-500 mL). Thirty-two patients (45%) had imaging 4-24 h post-dose with Diatrizoate Meglumine being present in the large intestine in 75% of these images. Intestinal obstruction or constipation resolved in 90% of patients post-dose. CONCLUSION: Most clinicians used 50 mL of Diatrizoate Meglumine as a single dose and repeated imaging after 4-24 h. Diatrizoate Meglumine was well tolerated and may be effective in resolving intestinal obstruction and constipation in patients with advanced neoplasms. Quality controlled studies are needed to further guide the use of Diatrizoate Meglumine in intestinal obstruction and constipation in patients with advanced neoplasms.


Assuntos
Constipação Intestinal/tratamento farmacológico , Constipação Intestinal/etiologia , Meios de Contraste/uso terapêutico , Diatrizoato de Meglumina/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Obstrução Intestinal/etiologia , Neoplasias/complicações , Adulto , Idoso , Idoso de 80 Anos ou mais , Austrália , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos Retrospectivos
4.
Pediatr Int ; 60(8): 714-718, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29804321

RESUMO

BACKGROUND: Intestinal disorders are common in very low-birthweight infants. The purpose of this study was to evaluate the impact of prophylactic oral Gastrografin® (diatrizoate acid) on meconium-related ileus (MRI) in extremely preterm infants. METHODS: This was a retrospective case-control study of infants born extremely preterm at <28 weeks of gestation and treated with diatrizoate acid (prophylactic group) or not (control group) in the periods 2007-2014 and 2000-2009, respectively. In the 2007-2014 period, 120 infants received prophylactic diatrizoate acid solution. From the 165 infants in the control group, we selected 120 infants matched for gestational age. Cases of death before 72 h of life or congenital abnormalities were excluded. Intestinal disorders, time until full enteral feeding, duration of hospital stay, mortality rate, and neurodevelopmental outcome were compared. RESULTS: MRI occurred in six infants in the control group and in none of the infants in the prophylactic group (P = 0.039). Median time until full enteral feeding was 25 versus 22 days (P < 0.01), hospital stay was 142 versus 126 days (P < 0.01), and mortality rate for infants aged 24-27 weeks was 8.2% versus 0% (P = 0.021), respectively. CONCLUSIONS: Prophylactic oral diatrizoate acid reduced MRI in extremely preterm infants without side-effects and decreased the mortality rate of infants born at 24-27 weeks, and is thus beneficial in extremely preterm infants.


Assuntos
Diatrizoato de Meglumina/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Lactente Extremamente Prematuro , Doenças do Prematuro/prevenção & controle , Íleo Meconial/prevenção & controle , Administração Oral , Feminino , Humanos , Recém-Nascido , Modelos Logísticos , Masculino , Estudos Retrospectivos , Resultado do Tratamento
5.
Int J Colorectal Dis ; 32(7): 1051-1055, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28280961

RESUMO

PURPOSE: The aim of this study was to identify risk factors related with failure of conservative management of adhesive small bowel obstruction (ASBO) in patients with previous colorectal surgery. METHODS: Patients admitted with the diagnosis of ASBO after previous colorectal resection, were included. All patients underwent administration of Gastrografin®. Abdominal radiography was done after 24 h, to confirm the presence of contrast in colon (incomplete obstruction) or not (complete obstruction). Several factors were investigated to study their relationship with the failure of conservative management. Failure of conservative management was considered when emergency operation was needed to solve ASBO. RESULTS: Incomplete obstruction was observed in 174 episodes (93.0%) while in 13 (7.0%) was complete. One hundred seventy-one ASBO episodes (91.4%) responded successfully to nonoperative treatment and 16 (8.6%) required emergency surgery. Five patients needed bowel resection. Results on the diagnostic test with Gastrografin® showed a sensitivity of 75%, specificity of 99%, positive predictive value 92%, and negative predictive value 98%. Age over 75 years was the only predictive factor for failure of conservative management. The median waiting time from the radiologic confirmation of complete obstruction to surgery was higher in patients requiring bowel resection when compared to those who did not need resection. CONCLUSIONS: The use of Gastrografin® in ASBO after colorectal resection is a safe and useful tool for the indication of conservative management. Age over 75 years is a predictive factor for need of surgery. Surgery should be performed no later than the following 24 h of confirmed complete obstruction.


Assuntos
Cirurgia Colorretal/efeitos adversos , Tratamento Conservador , Diatrizoato de Meglumina/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Obstrução Intestinal/etiologia , Aderências Teciduais/tratamento farmacológico , Idoso , Humanos , Masculino , Análise Multivariada , Falha de Tratamento
6.
World J Surg ; 40(1): 206-14, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26446450

RESUMO

BACKGROUND: Postoperative ileus is a common problem with significant clinical and economic consequences. We hypothesized that Gastrografin may have therapeutic utility by accelerating the recovery of postoperative ileus after colorectal surgery. The aim of this trial was to study the impact of oral Gastrografin administration on postoperative prolonged ileus (PPI) after elective colorectal surgery. METHODS: The main endpoint of this randomized, double-blinded, controlled trial was time of resolution of PPI. The secondary endpoints were overall hospital length of stay, time to start oral intake, time to first passage of flatus or stools, time of need of nasogastric tube, and need of parenteral nutrition. Included criteria were patients older than 18 years, operated for colonic neoplasia, inflammatory bowel disease, or diverticular disease. There were two treatments: Gastrografin administration and placebo. The sample size was calculated taking into account the average length of postoperative ileus after colorectal resection until tolerance to oral intake. Statistical analysis showed that 29 subjects in each group were needed. RESULTS: Twenty-nine patients per group were randomized. Groups were comparable for age, gender, ASA Physical Status Classification System, stoma construction, and surgical technique. No statistical differences were observed in mean time to resolution between the two groups, 9.1 days (CI 95%, 6.51-11.68) in Gastrografin group versus 10.3 days (CI 6.96-10.29) in Placebo group (P = 0.878). Even if not statistically significant, time of resolution of PPI, overall length of stay, time of need of nasogastric tube, and time to tolerance of oral intake were shorter in the G group. CONCLUSIONS: Gastrografin does not accelerate significantly the recovery of prolonged postoperative ileus after elective colorectal resection when compared with placebo. However, it seems to clinically improve all the analyzed variables.


Assuntos
Cirurgia Colorretal/efeitos adversos , Diatrizoato de Meglumina/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Íleus/tratamento farmacológico , Idoso , Método Duplo-Cego , Feminino , Humanos , Íleus/etiologia , Intubação Gastrointestinal , Masculino , Pessoa de Meia-Idade , Cuidados Pós-Operatórios/métodos , Complicações Pós-Operatórias , Fatores de Tempo
8.
Pediatr Surg Int ; 31(12): 1171-6, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26428224

RESUMO

OBJECTIVE: Ascaris-induced small bowel obstruction (SBO) is a common sequel of Ascaris lumbricoides (AL) infestation. Most cases respond to conservative treatment practiced in different centers worldwide. We conceived a prospective randomized trial to compare the conservative treatment with gastrografin administered in addition to the conservative treatment. STUDY DESIGN: This prospective randomized study was conducted between January 2011 and June 2014 at Department of Paediatric and Neonatal Surgery, a tertiary-care hospital. Patients were divided into two groups, one group received conservative treatment and the other received gastrografin in addition to conservative treatment. Forty patients having uncomplicated AL-induced SBO were included in each group. Gastrografin was administered through nasogastric tube and serial clinical and radiological monitoring was performed. The duration of hospital stay, time between admission and first oral feed, passage of worms/flatus were compared in the two groups. Student's t test was used for comparing these variables. RESULTS: Average time for passage of flatus or worms and resolution of abdominal signs and was shorter in gastrografin group as compared to the conservative group. This difference was found to be statistically significant. The average duration of hospital stay in gastrografin group was 25.20 ± 8.01 h whereas it was 61.12 ± 14.64 h in the conservative group (P < 0.001). The difference in the operation rate was statistically insignificant (2 in gastrografin group and 3 in the conservative group).No serious adverse reaction was noted after gastrografin administration. CONCLUSION: Use of gastrografin resulted in faster relief of signs and symptoms of AL-induced SBO, early passage of worms/flatus and return to oral feeds. However, the role of gastrografin role in reducing the likelihood of laparotomy remains inconclusive. Adverse effects of gastrografin can be prevented if it is used in well-hydrated patients.


Assuntos
Ascaríase/complicações , Ascaríase/tratamento farmacológico , Diatrizoato de Meglumina/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Obstrução Intestinal/parasitologia , Animais , Ascaris , Criança , Meios de Contraste/uso terapêutico , Gerenciamento Clínico , Feminino , Humanos , Índia , Obstrução Intestinal/diagnóstico por imagem , Intestino Delgado/diagnóstico por imagem , Intestino Delgado/parasitologia , Tempo de Internação/estatística & dados numéricos , Masculino , Estudos Prospectivos , Radiografia , Resultado do Tratamento
10.
Korean J Parasitol ; 52(6): 677-80, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25548421

RESUMO

Infection cases of diphyllobothriid tapeworms are not much in the below teen-age group. We report a case of Diphyllobothrium nihonkaiense infection in a 13-year-old boy. He presented with severe fatigue, occasional abdominal pain at night time. He also had several episodes of tapeworm segment discharge in his stools. By his past history, he had frequently eaten raw fish including salmon and trout with his families. Numerous eggs of diphyllobothriid tapeworm were detected in the fecal examination. We introduced amidotrizoic acid as a cathartic agent through nasogastroduodenal tube and let nearly whole length (4.75 m) of D. nihonkaiense be excreted through his anus. After a single dose of praziquantel, the child's stool showed no further eggs, and his symptoms disappeared. The evacuated worm was identified as D. nihonkaiense by mitochondrial cox1 gene analysis. Here we report a successful extracorporeal worm extraction from an infection case of D. nihonkaiense by the injection of amidotrizoic acid.


Assuntos
Antiparasitários/uso terapêutico , Diatrizoato de Meglumina/uso terapêutico , Difilobotríase/tratamento farmacológico , Diphyllobothrium/efeitos dos fármacos , Diphyllobothrium/isolamento & purificação , Adolescente , Animais , Ciclo-Oxigenase 1/genética , Difilobotríase/parasitologia , Difilobotríase/patologia , Diphyllobothrium/classificação , Diphyllobothrium/genética , Fezes/parasitologia , Humanos , Masculino , Praziquantel/uso terapêutico , Análise de Sequência de DNA
11.
Arq Bras Cir Dig ; 36: e1777, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38088723

RESUMO

BACKGROUND: Adhesive small bowel obstruction is one of the most common causes of surgical emergencies, representing about 15% of hospital admissions. Defining the need and timing of surgical intervention still remains a challenge. AIMS: To report the experience of using meglumine-based water-soluble contrast in a tertiary hospital in southern Brazil, comparing with the world literature. METHODS: Patients suspected of having adhesive small bowel obstruction, according to their clinical conditions, underwent an established protocol, consisting of the administration of water-soluble contrast, followed by plain abdominal radiograph within 12 hours and by a new clinical evaluation. The protocol was initiated after starting conservative management, including fasting and placement of a nasogastric tube, as well as intravenous fluid reposition. RESULTS: A total of 126 patients were submitted to the protocol. The water-soluble contrast test sensitivity and specificity after the first radiograph were 94.6 and 91.0%, respectively; after the second radiograph, these values were 92.3 and 100%. The general test values for sensitivity and specificity were 91.9 and 100%, respectively. CONCLUSIONS: The measure parameters evaluated in this study were similar to those found in the literature, contributing to endorse the importance of this test in the evaluation of patients with adhesive small bowel obstruction. The particular relevance of this study was the similar results that were found using a different type of meglumine-based contrast, which is available in Brazil.


Assuntos
Diatrizoato de Meglumina , Obstrução Intestinal , Humanos , Diatrizoato de Meglumina/uso terapêutico , Aderências Teciduais/diagnóstico por imagem , Meios de Contraste/uso terapêutico , Obstrução Intestinal/diagnóstico por imagem , Obstrução Intestinal/cirurgia , Meglumina/uso terapêutico , Água
12.
Intern Med J ; 42(3): 323-9, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22432985

RESUMO

AIMS: Pneumatosis cystoides intestinalis (PCI) is a rare life-threatening gastrointestinal complication in the course of connective tissue disease (CTD). PCI is characterised by the appearance of intramural clusters of gas in the small and large bowel wall on X-ray or computed tomography and often is accompanied by free air in the peritoneal cavity. METHODS: We present three cases of PCI in patients with scleroderma-related conditions. A review of the English language literature published on MEDLINE from 1973 to 2008 was conducted using the terms: 'systemic sclerosis', 'connective tissue disease' and 'pneumatosis cystoides intestinalis'. This review focused on clinical features, diagnostic and treatment strategies of PCI in the context of CTD. RESULTS: Symptoms of PCI are non-specific: abdominal pain, vomiting, constipation, bloating and weight loss. Coexistence of PCI with other manifestations of CTD, such as intestinal pseudo-obstruction and/or bacterial overgrowth, complicates the clinical diagnosis. Treatment approach to PCI is mostly conservative: intestinal 'rest', parenteral nutrition, antibiotics, fluids and electrolyte supplementation, and inhaled oxygen. Surgical intervention should be performed only in cases of bowel perforation, ischaemia or necrosis. Patients with PCI have high mortality rates due to PCI itself but also to the severity and variety of basic CTD complications. CONCLUSION: Recognition of PCI, particularly in the context of underlying CTD, is necessary for proper therapeutic application. In patients with underlying CTD and symptoms of abdominal emergency, recruitment of multidisciplinary teams, including rheumatologist, gastroenterologist, imaging specialist and surgeons familiar with intestinal complications of CTD-related conditions, is warranted.


Assuntos
Pneumatose Cistoide Intestinal/etiologia , Escleroderma Sistêmico/complicações , Abdome Agudo/etiologia , Corticosteroides/efeitos adversos , Corticosteroides/uso terapêutico , Adulto , Idoso , Doenças do Tecido Conjuntivo/complicações , Diagnóstico Diferencial , Diatrizoato de Meglumina/uso terapêutico , Evolução Fatal , Feminino , Humanos , Hipoalbuminemia/etiologia , Imunoglobulinas Intravenosas/uso terapêutico , Obstrução Intestinal/diagnóstico , Pseudo-Obstrução Intestinal/etiologia , Pessoa de Meia-Idade , Octreotida/uso terapêutico , Omeprazol/uso terapêutico , Pneumatose Cistoide Intestinal/diagnóstico , Pneumoperitônio/etiologia , Polimiosite/complicações , Escleroderma Sistêmico/terapia , Síndrome de Sjogren/complicações , Síndrome de Sjogren/diagnóstico , Redução de Peso
13.
PLoS One ; 17(8): e0272915, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35951504

RESUMO

BACKGROUND: Meconium-related ileus in very low birth weight infants can lead to increased morbidity or mortality and prolonged hospitalization without prompt diagnosis and treatment. This study primarily aimed to identify the incidence of and factors associated with meconium-related ileus and secondarily sought to investigate clinical and growth outcomes after water-soluble contrast media (Gastrografin) enema. METHODS: We retrospectively reviewed medical records of very low birth weight infants born between February 2009 and March 2019 in the neonatal intensive care unit of a single medical center. Perinatal factors, clinical outcomes, and growth outcomes were compared between the group with meconium-related ileus that received Gastrografin enema and the control group. RESULTS: Twenty-four (6.9%) patients were diagnosed with meconium-related ileus among 347 very low birth weight infants. All achieved successful evacuation of meconium with an average of 2.8 (range: 1-8) Gastrografin enema attempts without procedure-related complications. Initiation of Gastrografin enema was performed at mean 7.0 days (range: 2-16) after birth. Incidences of moderate to severe bronchopulmonary dysplasia were higher and the duration of mechanical ventilation and need for oxygen were longer in the meconium-related ileus group (P = 0.039, 0.046, 0.048, respectively). Meconium-related ileus infants took more time to start enteral feeding and the nothing per oral time was longer (P = 0.001 and 0.018, respectively). However, time to achieve full enteral feeding and Z-scores for weight and height at 37 weeks and at 6 months corrected age did not differ between the two groups. CONCLUSIONS: Gastrografin enema in very low birth weight infants with meconium-related ileus was an effective and safe medical management. Following Gastrografin enema, very low birth weight infants with meconium-related ileus achieved similar subsequent feeding progress and similar growth levels as the control groups without meconium-related ileus.


Assuntos
Íleus , Obstrução Intestinal , Diatrizoato de Meglumina/uso terapêutico , Enema/efeitos adversos , Humanos , Íleus/etiologia , Íleus/terapia , Recém-Nascido , Recém-Nascido de muito Baixo Peso , Obstrução Intestinal/etiologia , Mecônio , Estudos Retrospectivos
14.
Can J Surg ; 54(2): 123-7, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21251420

RESUMO

BACKGROUND: Gastrografin (GG) has been shown to accelerate the resolution of adhesive small bowel obstruction (ASBO) and decrease length of stay (LOS) in hospital. Consequently, we instituted a protocol recommending the routine use of GG in patients with ASBO. This study reviews patient outcomes after protocol implementation. METHODS: We conducted a retrospective review of all patients with ASBO from January 1997 to December 2007. Data were categorized by admission date and use of GG. The outcomes reviewed were protocol uptake, median LOS in hospital and operative rate. Results were analyzed using the Mann-Whitney U test and the 2-tailed Fisher exact test. RESULTS: There were 710 patients with ASBO overall. Sixteen of 376 (4.3%) patients received GG before institution of the protocol (period 1), whereas 195 of 334 (58.4%) received GG thereafter (period 2). In period 2, use of GG was limited to between 58% and 69% of all potentially eligible patients per year. Fifty-seven of 710 (8%) patients required surgery. In period 1, there were no significant differences in median LOS in hospital (p=0.29) and operative rate (p=0.65) between patients who received GG and those who were managed without GG. In period 2, patients receiving GG had a greater median LOS in hospital (3 [range 2-5] v. 2 [range 1-5] d, p=0.048) but significantly lower operative rates (5.1% v. 12.9%, p=0.018). Overall, the median LOS decreased over time (period 1: 4 [2-7] d v. period 2: 2 [1-5] d, p=0.010). The operative rate did not vary substantially between periods (7.7% v. 8.4%, p=0.42). CONCLUSION: The introduction of a protocol has increased the proportion of eligible patients receiving GG. However, protocol nonadherence and factors other than GG usage have influenced LOS in hospital and operative rates. Demonstrated benefits from previously published clinical trials have thus not been replicated within our setting.


Assuntos
Meios de Contraste/uso terapêutico , Diatrizoato de Meglumina/uso terapêutico , Obstrução Intestinal/terapia , Protocolos Clínicos , Feminino , Humanos , Obstrução Intestinal/patologia , Obstrução Intestinal/cirurgia , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Aderências Teciduais
15.
Neurogastroenterol Motil ; 33(5): e14046, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33252179

RESUMO

BACKGROUND: Postoperative ileus is common and is a major clinical problem. It has been widely studied in patients and in experimental models in laboratory animals. A wide variety of treatments have been tested to prevent or modify the course of this disorder. PURPOSE: This review draws together information on animal studies of ileus with studies on human patients. It summarizes some of the conceptual advances made in understanding the mechanisms that underlie paralytic ileus. The treatments that have been tested in human subjects (both pharmacological and non-pharmacological) and their efficacy are summarized and graded consistent with current clinical guidelines. The review is not intended to provide a comprehensive overview of ileus, but rather a general understanding of the major clinical problems associated with it, how animal models have been useful to elucidate key mechanisms and, finally, some perspectives from both scientists and clinicians as to how we may move forward with this debilitating yet common condition.


Assuntos
Sistema Nervoso Entérico/fisiopatologia , Motilidade Gastrointestinal/fisiologia , Íleus/fisiopatologia , Complicações Pós-Operatórias/fisiopatologia , Sistema Nervoso Simpático/fisiopatologia , Anestesia Epidural , Animais , Benzofuranos/uso terapêutico , Goma de Mascar , Colinérgicos/uso terapêutico , Meios de Contraste/uso terapêutico , Inibidores de Ciclo-Oxigenase/uso terapêutico , Diatrizoato de Meglumina/uso terapêutico , Procedimentos Cirúrgicos do Sistema Digestório/métodos , Recuperação Pós-Cirúrgica Melhorada , Nutrição Enteral , Hidratação , Fármacos Gastrointestinais/uso terapêutico , Grelina/uso terapêutico , Humanos , Íleus/imunologia , Íleus/prevenção & controle , Íleus/terapia , Inflamação/imunologia , Pseudo-Obstrução Intestinal/imunologia , Pseudo-Obstrução Intestinal/fisiopatologia , Pseudo-Obstrução Intestinal/prevenção & controle , Pseudo-Obstrução Intestinal/terapia , Intubação Gastrointestinal , Laparoscopia , Mastócitos/imunologia , Piperidinas/uso terapêutico , Complicações Pós-Operatórias/imunologia , Complicações Pós-Operatórias/prevenção & controle , Complicações Pós-Operatórias/terapia , Agonistas do Receptor 5-HT4 de Serotonina/uso terapêutico , Simpatolíticos/uso terapêutico
16.
J Surg Res ; 162(2): 170-6, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19524265

RESUMO

BACKGROUND: Many studies have shown that gastrografin can be used for diagnosis of adhesive small bowel obstruction (ASBO) and for assessing the need for surgical intervention. However, several studies have reported conflicting results. Therefore, the aim of this study is to assess the diagnostic and therapeutic effect of gastrografin in ASBO. PATIENTS AND METHODS: Altogether, 110 patients with ASBO were randomized into control and gastrografin groups. In the gastrografin group, 100 mL of the dye was administered through a nasogastric tube. Obstruction was considered complete if the contrast failed to reach the colon on the 24-h film. Patients with gastrografin in the colon within 24 h after dye administration were considered as partially obstructed, and were submitted to nonoperative treatment. The patients were operated on if they developed signs of strangulation or failed to improve within 48 h. RESULTS: The overall operative rate was 14.5% in gastrografin group versus 34.5% in control group, P=0.04. The time from admission to resolution of symptoms was significantly lower in gastrografin group (19.5 versus 42.6 h, P=0.001), and the length of hospital stay was shorter in gastrografin group (3.8 versus 6.9 d 0.002), and in nonoperative patients (3.1 versus 5.1 days). Sensitivity, specificity, positive predictive value, and negative predictive value for gastrografin follow-through as an indicator for operative treatment of ASBO were 87.5%, 100%, 100 % , and 97.9%, respectively. CONCLUSIONS: Oral gastrografin helps in the management of ASBO. Oral gastrografin is safe and reduces the operative rate and time of resolution as well as hospital stay.


Assuntos
Diatrizoato de Meglumina/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Obstrução Intestinal/cirurgia , Adulto , Idoso , Meios de Contraste/uso terapêutico , Egito , Serviço Hospitalar de Emergência , Feminino , Humanos , Obstrução Intestinal/etiologia , Laparotomia/efeitos adversos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Seleção de Pacientes , Recidiva , Reoperação/estatística & dados numéricos , Resultado do Tratamento , Adulto Jovem
17.
J Pediatr Gastroenterol Nutr ; 50(2): 173-8, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19668004

RESUMO

OBJECTIVES: Patients with cystic fibrosis (CF) presenting with meconium ileus (MI) tend to have worse outcomes than those without MI. We evaluated the clinical characteristics and survival rates among Israeli patients with CF with and without MI after a prolonged follow-up (15-30 years). PATIENTS AND METHODS: A multicenter retrospective study. Forty-nine patients with CF, representing 13.8% of all patients with CF in Israel, presented with MI (current age 17.4 +/- 7.9 years) between 1975 and 2006. They were compared with 38 patients with CF (current age 19.3 +/- 6.5 years) without MI matched by sex and CF transmembrane conductance regulator mutation. RESULTS: A total of 66.2% of patients with MI and 73.6% without MI were followed for a prolonged period (24.9 +/- 2.7 years). Of the patients with MI, 31 were managed operatively, whereas 18 were treated successfully with gastrograffin enema, with similar clinical outcomes. Five patients in the MI group and 3 in the control group died during the study period. Bacterial colonization, z score of body mass index, and pulmonary function tests were similar in patients with and without MI in the long term. In younger patients, many clinical parameters were more prevalent in patients with MI (P = 0.004). However, these differences disappeared after the long-term follow-up (up to 31-years). CONCLUSIONS: Patients with CF presenting with MI had similar pulmonary function and nutritional status, as well as survival rates as did the control patients without MI. The distinct genetic mutation found in our population may explain in part the favorable results compared with other studies. In addition, it seems that early diagnosis and treatment of MI in patients with CF may be beneficial, subsequently lowering morbidity, and increasing survival.


Assuntos
Fibrose Cística/complicações , Íleus/complicações , Mecônio , Adolescente , Adulto , Fatores Etários , Índice de Massa Corporal , Criança , Fibrose Cística/mortalidade , Fibrose Cística/terapia , Diatrizoato de Meglumina/uso terapêutico , Progressão da Doença , Enema , Feminino , Humanos , Íleus/terapia , Lactente , Israel , Pulmão , Masculino , Testes de Função Respiratória , Estudos Retrospectivos , Fatores de Risco , Análise de Sobrevida , Resultado do Tratamento , Adulto Jovem
18.
ANZ J Surg ; 89(3): 239-243, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30294848

RESUMO

BACKGROUND/AIM: Faecal impaction (FI) is a common cause of lower gastrointestinal tract obstruction. Gastrografin is a water-soluble radiologic contrast agent that may be orally or rectally administered, with proved therapeutic benefits in adhesive small bowel obstruction. Enemas have long been advocated as the best treatment for FI. The purpose of this study was to demonstrate that enteral administration of gastrografin might be more effective than enema in FI treatment inducing intestinal obstruction. METHODS: A double-blinded, controlled and randomized trial was conducted. Participants received 100 mL of gastrografin (gastrografin group) through nasointestinal tube or enemas (enema group) once daily for six consecutive days. Successful faecal disimpaction, FI time to resolution, Bristol Stool Scale, constipation severity, symptom assessment and adverse events were evaluated. RESULTS: A total of 124 patients were eligible, but only 83 were enrolled to this trial (mean age: 44 ± 15.8 years). Forty-two patients received enemas, and 41 patients received gastrografin, with six dropouts in each group. Successful disimpaction was achieved with enemas (69.44%) and gastrografin (88.57%; P = 0.034), mean duration of impaction was strikingly different between the two groups (67.13 versus 31.67, respectively; P < 0.01). Constipation severity and symptom assessment were significantly reduced in the gastrografin group. CONCLUSION: Gastrografin given through nasointestinal tube was more effective than enema in the treatment of FI inducing colon obstruction. Gastrografin might be taken into consideration as an effective and safe therapeutic option for FI.


Assuntos
Constipação Intestinal/complicações , Diatrizoato de Meglumina/uso terapêutico , Impacção Fecal/tratamento farmacológico , Impacção Fecal/etiologia , Adolescente , Adulto , Idoso , Método Duplo-Cego , Enema , Impacção Fecal/terapia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Índice de Gravidade de Doença , Adulto Jovem
19.
J Med Life ; 12(1): 10-14, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31123519

RESUMO

The use of Gastrografin may have a therapeutic effect on resolving adhesive small bowel obstruction. Adhesive Small Bowel obstruction (ASBO) accounts for the majority of patients with small bowel obstruction. Most patients are managed conservatively; frequent admissions create a considerable burden. We sought to examine the adherence to the Bologna guidelines for the management of ASBO in a high volume tertiary center and whether or not Gastrografin had a therapeutic effect. A comparison was made between an initial retrospective audit looking at ASBO and a prospective re-audit after applying standards derived from the Bologna guidelines. During re-audit it was found that more patients underwent conservative management and fewer patients had surgery as first line management. In the re-audit, those who had to undergo surgery within/after a period of 72h of conservative management were also fewer. Whether they were managed surgically primarily or after a period of conservative management, the average length of stay was also shorter. In comparison to the preliminary audit, there appeared to be no change in the way that medical history and physical examination was documented during the re-audit. However, there was a marked difference in the use of appropriate blood tests and CT scans. Changes were made successfully following the initial audit results and have been implemented, thus closing the audit loop. This study shows that the use of Gastrografin has decreased the need for surgical intervention in a group of patients with small bowel obstruction.


Assuntos
Diatrizoato de Meglumina/administração & dosagem , Diatrizoato de Meglumina/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Aderências Teciduais/tratamento farmacológico , Diatrizoato de Meglumina/farmacologia , Humanos , Obstrução Intestinal/complicações , Obstrução Intestinal/diagnóstico por imagem , Estudos Prospectivos , Padrões de Referência , Estudos Retrospectivos , Aderências Teciduais/complicações , Aderências Teciduais/diagnóstico por imagem
20.
Am J Surg ; 217(6): 1016-1018, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30621907

RESUMO

BACKGROUND: One of the most common reasons for admission to a surgical service is for a partial small bowel obstruction. There is considerable variation in management. Several studies suggest that the use of diatrizoate (Gastrografin), a hyperosmolar contrast agent, can be helpful as a diagnostic agent as well as possibly therapeutic, reducing the need for operative intervention. There is a paucity of data on the use of Gastrografin in the community setting. We hypothesized that this standardized algorithm of Gastrografin administration would decrease the need for surgery and shorten a patient's length of stay, even outside the confines of a regulated clinical trial. METHODS: We performed a retrospective review of all patients admitted to two major hospitals in our network with the diagnosis of partial small bowel obstruction. Patients were excluded if they were admitted within thirty days of bowel surgery or if they were <18 years of age. The primary variable for analysis was the subsets of patients who were placed on our protocol versus no protocol at the other hospital. The primary outcome was hospital length of stay. Secondary outcomes included rate of surgery during the same admission and readmission within 30 days of discharge. All analyses were performed using Fisher's Exact test of Mann-Whitney U Test, as appropriate. RESULTS: A total of 1302 patients with partial small bowel obstruction were identified (103 on-protocol and 1199 off-protocol at our sister hospital). On-protocol patients had a shorter duration of hospitalization (mean, 4.9 days vs. 6.0 days, p < 0.001), lower rates of surgery (2% vs. 16%, p < 0.001), and similar rates of readmission for the same diagnosis (8% and 5%, p = 0.26), compared to off-protocol patients at our sister institution. CONCLUSION: A protocol utilizing Gastrografin for the management of partial small bowel obstruction decreases the need for surgery and shortens a patient's length of stay in a diverse community setting.


Assuntos
Diatrizoato de Meglumina/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Intestino Delgado , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Protocolos Clínicos , Meios de Contraste , Feminino , Humanos , Obstrução Intestinal/diagnóstico por imagem , Obstrução Intestinal/cirurgia , Intestino Delgado/diagnóstico por imagem , Intestino Delgado/cirurgia , Tempo de Internação/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa